Evidence map›Paper›PMID 31895348›Full record

ReviewTransplantation2020

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.

Carrie A Schinstock, Roslyn B Mannon, Klemens Budde, Anita S Chong, Mark Haas, Stuart Knechtle, Carmen Lefaucheur, Robert A Montgomery, Peter Nickerson, Stefan G Tullius and 16 more

Registry-linked trialOpen access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06708988 (Predictors of Outcome of Pediatric Renal Transplantation), which is not on this map. Cited by 154 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 4 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06708988 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Predictors of Outcome of Pediatric Renal Transplantation

Typeobservational_patient_registrySponsorAssiut UniversityRan2025 to 2025Enrolled20ConditionsPediatric Renal Transplantation Complication
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 4 syntheses or guidelines pooled it, 313 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism.Transplant international : official journal of the European Society for Organ Transplantation · 2021
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Tailoring HLA antibody monitoring post-transplantation.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 8 countries.

Carrie A SchinstockMayo Clinic William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
Roslyn B MannonDivision of Nephrology, University of Alabama at Birmingham, Birmingham, AL.
Klemens BuddeDepartment of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.
Anita S ChongSection of Transplantation, Department of Surgery, The University of Chicago, Chicago, IL.
Mark HaasDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Stuart KnechtleDuke Transplant Center, Department of Surgery, Duke University School of Medicine, Durham, NC.
Carmen LefaucheurUniversité de Paris, Department of Transplantation, Saint Louis Hospital, Paris, France.
Robert A MontgomeryNYU Langone Transplant Institute, New York, NY.
Peter NickersonTransplant Immunology Laboratory, Shared Health and Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
Stefan G TulliusDivision of Transplant Surgery and Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Curie AhnTransplantation Center, Seoul National University Hospital, Seoul, Korea.
Medhat AskarBaylor University Medical Center, Transplant Immunology, Dallas, TX.
Marta CrespoDepartment of Nephrology, Hospital del Mar and Institute Hospital del Mar for Medical Research, Barcelona, Spain.
Steven J ChadbanDepartment of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia.
Sandy FengDepartment of Surgery, University of California San Francisco, San Francisco, CA.
Stanley C JordanComprehensive Transplant Center, Cedars-Sinai Medical Center, West Hollywood, CA.
Kwan ManDepartment of Surgery, The University of Hong Kong, Hong Kong, People's Republic of China.
Michael MengelDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Randall E MorrisStanford University School of Medicine, Stanford, CA.
Inish O'DohertyCritical Path Institute, Tucson, AZ.
Binnaz H OzdemirDepartment of Pathology, Baskent University, School of Medicine, Ankara, Turkey.
Daniel SeronNephrology Department, Hospital Vall d'Hebron, Autonomous University of Barcelona, Catalonia, Spain.
Anat R TamburComprehensive Transplant Center, Northwestern University, Chicago, IL.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Jean-Luc TaupinLaboratory of Immunology and Histocompatibility, Hôpital Saint-Louis APHP, Paris, France.
Philip J O'ConnellCentre for Transplant and Renal Research, Westmead Institute of Medical Research, University of Sydney and Renal Unit, Westmead Hospital, NSW, Australia.
University of Alabama at Birmingham · USCedars-Sinai Medical Center · USDuke University · USMiami Transplant Institute · USBaşkent University · TRBrigham and Women's Hospital · USCharité - Universitätsmedizin Berlin · DESeoul National University Hospital · KRStanford University · USUniversity of Alberta · CAUniversity of Chicago · US

Funding

Senescent cells drive mt-DNA accumulation and inflamm-agingR01AG064165 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI TULLIUS, STEFAN GUNTHER · 2020 to 2024
$2.6M
The microbiota and allograft rejection: novel investigations into the consequences of obesityU01AI132898 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ALEGRE, MARIA-LUISA, PERKINS, DAVID LINN · 2017 to 2021
$2.3M
NIAID NIH HHS U01 AI132898NIA NIH HHS R01 AG064165
6 · The paper itself

Abstract

With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed to improve patient outcomes.

Indexed as

ConsensusKidney TransplantationSocieties, MedicalAntilymphocyte SerumGraft RejectionHumansImmunosuppression TherapyIsoantibodiesTissue DonorsAntilymphocyte SerumIsoantibodies

Identifiers

PMID31895348
PMCPMC7176344
OpenAlexW2998211851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.